Michael Jones

发表

Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.

J. M. Clancy, P. O'Byrne, V. Holland, 2009, Journal of medicinal chemistry.

Discovery of a "true" aspirin prodrug.

J. M. Clancy, C. Carolan, J. Gilmer, 2008, Journal of medicinal chemistry.

Mechanisms of aggregation inhibition by aspirin and nitrate‐aspirin prodrugs in human platelets

M. Radomski, M. Santos-Martinez, J. Gilmer, 2012, The Journal of pharmacy and pharmacology.

Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates.

Nuna C. P. Araújo, V. Barton, P. Stocks, 2009, Bioorganic & medicinal chemistry letters.

Antitumour and antimalarial activity of artemisinin-acridine hybrids.

J. Baird, I. Piantanida, B. K. Park, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines.

B. K. Park, James Chadwick, P. Stocks, 2010, Bioorganic & medicinal chemistry.

In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?

D. Kerins, J. Gilmer, M. Ledwidge, 2012, Atherosclerosis.

Differential inhibition of tumour cell‐induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin

M. Radomski, M. Santos-Martinez, J. Gilmer, 2012, British journal of pharmacology.

Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs.

Ruth H. Hughes, Peter D Gibbons, V. Barton, 2007, Angewandte Chemie.

Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs.

Ruth H. Hughes, R. Amewu, G. Biagini, 2007, Angewandte Chemie.